Novel CD123-Targeting Antibody–Drug Conjugate Pivekimab Sunirine for Relapsed or Refractory AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Lancet Oncol 2024 Mar 01;25(3)388-399, NG Daver, P Montesinos, DJ DeAngelo, ES Wang, N Papadantonakis, E Todisco, KL Sweet, N Pemmaraju, AA Lane, L Torres-Miñana, JE Thompson, MY Konopleva, CM Sloss, K Watkins, G Bedse, Y Du, KE Malcolm, PA Zweidler-McKay, HM KantarjianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.